PUBLICATIONS IN PEER REVIEWED JOURNALS



2015


Fascì-Spurio F, Pavlidis P, Bjarnason I. A new form of chronic inflammatory bowel disease associated with chronic liver disease.
Scand J Gastroenterol. 2016 Jan 5:1-2.

 

Bjarnason I, Hayee B, Pavlidis P, Kvasnovsky C, Scalori A, Sisson G, Charlesworth A, Shaikh H, Bjornsson E, Heneghan MA. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis. EBioMedicine. 2015 Sep 2;2(10):1523-7. doi: 10.1016/j.ebiom.2015.08.041.

 

Pavlidis P, Bjarnason I. Aspirin Induced Adverse Effects on the Small and Large Intestine. Curr Pharm Des. 2015;21:5089-93.


Kvasnovsky CL, Bjarnason I, Papagrigoriadis S. What colorectal surgeons should know about probiotics: a review. Colorectal Dis. 2015;17:840-8. doi: 10.1111/codi.13046.


Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: 

bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther. 2015 Oct;42(7):802-17. doi: 10.1111/apt.13333.


Pavlidis P, Potts J, Barnabas A, Heaton N, Bjarnason I, Heneghan M, Hayee B. Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation. Liver Transpl. 2015 Nov;21:1455-6. doi: 10.1002/lt.24212.


Sideris M, Adams K, Moorhead J, Diaz-Cano S, Bjarnason I, Papagrigoriadis. BRAFV600E mutation in colorectal cancer is associated with right-sided tumors and iron deficiency. Anticancer Research 2015;35:2345-2350


Dobbs SM, Dobbs RJ, Weller C, Charlett A, Augustin A, Taylor D, Ibrahim MA, Bjarnason I. Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol. 2016;22:22-32. doi: 10.1007/s13365-015-0357-8.


Hreinsson JP, Bjarnason I, Bjornsson ES. The outcome and role of drugs in patients with unexplained gastrointestinal bleeding. Scand J Gastroenterol. 2015;50:1482-9. 

doi: 10.3109/00365521.2015.1057861


Kvasnovsky CL, Haji A, Ryan S, Lin SL, Bjarnason I, Papagrigoriadis S. Utilization of 

High-frequency Mini Probe Ultrasound in the Assessment of Colonic Wall Thickness in Patients With Diverticular Disease: A Feasibility Study. Surg Laparosc Endosc Percutan Tech. 2015;25:205-8.


Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:255-63. 

doi: 10.3109/00365521.2014.966753.


Rainsford KD, Bjarnason I. Gastrointestinal adverse reactions from ibuprofen. In. Rainsford KD ed. Ibuprofen. Discovery, development and therapeutics. Wiley Blackwell, Chischester, 

W Sussex 2015:363-429


Bjarnason I, Adler SN, Sakamoto C. Physical-chemical small bowel injury. In Keuchel M, Hagenmuller F, Tajiri H eds. Video Capsule Enteroscopy. A Reference Guide and Atlas. 

Springer Heidelberg, New York, Dordrecht, London. 2015:295-301

 

 

2014


Bjarnason I, Adler SN, Sakamoto C. Physical-Chemical small intestinal injury. In Keuchel et al (eds). Video Capsule Endoscopy. A Reference Guide and Atlas. Springer-Verlag, Berlin, Heidelberg. 2014:295-302

 

Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2014 Oct 14:1-9.


Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.Aliment Pharmacol Ther. 2014;40:51-62.


Haji A, Adams K, Bjarnason I, Papagrigoriadis S  High-frequency mini probe ultrasound before endoscopic resection of colorectal polyps--is it useful?  Dis Colon Rectum. 2014;57:378-82.


Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with nonsteriodal anti-inflammatory drugs and other medications: a systematic review and meta-analysis. Colorectal Dis. 2014;16:O189-96.


Bjarnason I, Sherwood RA. Clinical biochemistry of the gastrointestinal tract. In Marshall WJ, Lapsley M, Day AP, Ayking RM (eds). Clinical Biochemistry. Metabolic and Clinical aspects. 3rd Edition. Churchill Livingstone, Edinburgh. 2014;214-230



2013


Kvasnovsky CL, Papagrioriadis S, Bjarnason I. Increased diverticular complications with NSAIDs and other medications: a systematic review and meta-analysis. Colorectal Dis. 2013 Dec 9. doi: 10.1111/codi.12516.

Blaecher C, Smet A, Flahou B, Pasmans F, Ducatelle R, Taylor D, Weller C, Bjarnason I, Charlett A, Lawson AJ, Dobbs RJ, Dobbs SM, Haesebrouck F. Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Pharmacol Ther. 2013;38:1347-53.

Dobbs SM, Charlett A, Dobbs RJ, Weller C, Iguodala O, Smee C, Lawson AJ, Taylor D, Bjarnason I Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter. 2013;18:187-96.

Bjarnason I. Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract Suppl. 2013;(178):37-42.

Haji A, Ryan S, Bjarnason I, Papagrigoriadis S. High-frequency mini-probe ultrasound as a useful adjunct in the management of patients with malignant colorectal polyps. Colorectal Dis. 2013;15:304-8.

Joshi D, Bjarnason I, Belgaumkar A, O'Grady J, Suddle A, Heneghan MA, Aluvihare V, Rela M, Heaton N, Agarwal K. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int. 2013;33:53-61. 



2012


Adler SN, Bjarnason I. What we have learned and what to expect from capsule endoscopy. World J Gastrointest Endosc. 2012;4:448-452.

Dobbs RJ, Charlett A, Dobbs SM, Weller C, A Ibrahim MA, Iguodala O, Smee C, Plant JM, Lawson AJ, Taylor D, Bjarnason I. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog. 2012;4:12. doi: 10.1186/1757-4749-4-12.

Haji A, Ryan S, Bjarnason I, Donaldson N, Papagrigoriadis S. Colonoscopic high frequency mini-probe ultrasound is more accurate than conventional computed tomography in the local staging of colonic cancer. Colorectal Dis. 2012;14:953-995. doi: 10.1111/j.1463-1318.2011.02871.x.

Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, Kalra PR, Buhner S, Herrmann R, Springer J, Doehner W, von Haehling S, Anker SD, Rauchhaus M. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2012 May 17;157(1):80-5. doi: 10.1016/j.ijcard.2010.12.016. Epub 2010 Dec 28.

Rainsford KD, Bjarnason I. NSAIDs: take with food or after fasting? J Pharm Pharmacol. 2012;64:465-469.

Dobbs RJ, Charlett A, Dobbs SM, Weller C, Iguodala O, Smee C, Bowthorpe J, Taylor D, Bjarnason IT. Towards defining a rigidity-associated pathogenic pathway in idiopathic parkinsonism. Neurodegener Dis. 2012;10:183-6.

Bjarnason I, Zeino Z, Sisson G. Drug-induced dmage to the small and large intestine. Textbook of Clinical Gastroenteology and Hepatology (2nd ed). Eds: Hawkey CJ, Bosch J, Richter JE, Garcia-Tsao G, Chan FC.  Wiley-Blackwell. 2012: 498-504


2011


Dobbs RJ, Charlett A, Dobbs SM, Weller C, Iguodala O, Smee C, Bowthorpe J, Taylor D, Bjarnason IT. Towards Defining a Rigidity-Associated Pathogenic Pathway in Idiopathic Parkinsonism. Neurodegener Dis. 2011 Dec 23.

Joshi D, Bjarnason I, Belgaumkar A, O'Grady J, Suddle A, Heneghan MA, Aluvihare V, Rela M, Heaton N, Agarwal K. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int. 2011 Nov 22. doi: 10.1111/j.1478-3231

Bjarnason I. Commentary: We came to an overwhelming and uniform opinion that these reports do not show colitis. BMJ. 2011;343:1136

Haji A, Ryan S, Bjarnason I, Donaldson N, Papagrigoriadis S. Colonoscopic high frequency mini probe ultrasound is more accurate than conventional computed tomography (CT) in the local staging of colonic cancer. Colorectal Dis. 2011 Nov 5. doi: 10.1111/j.1463-1318.2011.02871.x.

Sisson G, Bjarnason I. Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents. Inflammopharmacology. 2011; 4:183-186.

Tanaka T, Hiroyuki Hanai H, Bjarnason I. Adacolumn Therapeutic Leucocytapheresis for Ulcerative Colitis: Clinical and Endoscopic Features of Responders and Unresponders to this Nonpharmacologic Intervention. J Gastrointest Digest Sys 2011, 1:2

Intervention. J Gastrointest Digest Sys 2011, 1:2http://dx.doi.org/10.4172/jgds.1000104

Sisson G, Takeutchi K, Bjarnason I. Nonsteroidal anti-inflammatory drugs and IBD. In Advanced Therapy in Inflammatory Bowel Disease (3rd ed), Eds: Bayless TM and Haunauer SB. People’s Medical Publishing House-USA, Shelton Conneticut 2011:239-243


2010


Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, Kalra PR, Buhner S, Herrmann R, Springer J, Doehner W, von Haehling S, Anker SD, Rauchhaus M. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2010

Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin L, Price AB, Ibrahim MA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, Peterson DW. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter. 2010;15:279-94.

Hotz-Behofsits C, Simpson RJ, Walley M, Bjarnason IT. Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents. Scand J Gastroenterol. 2010;45:822-7.

Zeino Z, Sisson G, Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin Gastroenterol. 2010;24:133-41.



2009


Charlett A, Dobbs RJ, Dobbs SM, Weller C, Ibrahim MA, Dew T, Sherwood R, Oxlade NL, Plant JM, Bowthorpe J, Lawson AJ, Curry A, Peterson DW, Bjarnason IT. Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathog. 2009;1:20-6.

Jeyarajah S, Faiz O, Bottle A, Aylin P, Bjarnason I, Tekkis PP, Papagrigoriadis S. Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions. Aliment Pharmacol Ther. 2009;30:1171-82.

Moore A, Bjarnason I, Cryer B, Garcia-Rodriguez L, Goldkind L, Lanas A, Simon L. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol. 200;7:1156-63.

Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, Ellis DS, Ibrahim MA, McCrossan MV, O'Donohue J, Owen RJ, Oxlade NL, Price AB, Sanderson JD, Sudhanva M, Williams J. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter. 2008 Oct;13(5):309-22.

Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol. 2009;44 (Suppl 19):23-9.


2008


Bjarnason A, Adler SN, Bjarnason I. Probiotic prophylaxis in predicted severe acute pancreatitis. Lancet. 2008 12;372:114-115.

Björnsson E, Westgaard G, Bjarnason I. Severe injury to the small bowel associated with a short course of diclofenac.Scand J of Gastroenterol. 2008;43:759-760

Maiden L, Takeuchi K, Baur R, Bjarnason II, O'Donohue J, Forgacs I, Chung-Faye G, Sanderson J, Bjarnason I. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008;14:1413-8.

Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-16.

Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. J R Soc Med. 2007;100 Suppl 48:11-14

Adler SN, Bjarnason I,Metzger YC. New balloon-guided technique for deep small-intestine endoscopy using standard endoscopes. Endoscopy. 2008;40:502-505

Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Forbes A, Bjarnason I, Sherwood RA, Ciclitira P, Nicholls JR. Faecal calprotectin: a non-invasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol. 2008;20:174-179.


2007


Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. J R Soc Med. 2007;100 Suppl 48:11-4.

Loganayagam A, Bjarnason I. Stool tests: Are they useful? in Tozun  N, Mantzaris G, Dagli U, Scholmeric J. IBD 2007-Achievements in research and clinical practice. Falk Symposium 159. Springer, Dordrecht, 2007:129-142

Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocyte apheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200

Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK.
Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007;369:614.

Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol. 2007;81:291-298

Leung WK, Bjarnason I, Chan FK. Low- dose aspirin and small bowel enteropathy  Lancet. 2007;369:1691.

Culkin A, Gabe SM, Bjarnason I, Grimble G, Madden AM, Forbes A. A double-blind, randomized, controlled crossover trial of glutamine supplementation in home parenteral nutrition. Eur J Clin Nutr. 2007

Adebayo D, Popat R, Thjodleifsson B, Bjarnason I.  Granulomatous ileitis in a patient with ankylosing spondylitis. Nat Clin Pract Gastroenterol Hepatol. 2007;4:347-351

Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther. 2007;26:95-106

Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I.  A common genetic background for inflammatory bowel disease and ankylosing spondylitis: A genealogic study in Iceland. Arthritis Rheum. 2007 30;56:2633-2639

Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I.  Long-Term Effects of Nonsteroidal Anti-Inflammatory Drugs and Cyclooxygenase-2 Selective Agents on the Small Bowel: A Cross-Sectional Capsule Enteroscopy Study. Clin Gastroenterol Hepatol. 2007

Bjarnason I, Scott D. NSAIDs and COX-2 selective agents: cause or cure of pain in IBD. Clinical dilemmas in Inflammatory Bowel Disease. Irving P, Rampton D, Shanahan F (eds). Blackwell Publishing, Oxford. 2006:136-138

Bjarnason I. The impact of recent data on our understanding of the roles of COX-1 and COX-2 in gastrointestinal physiology. Clinical Drug Investigation 2007;27 (suppl 1):7-13

Bjarnason I. Alcohol: A friend or foe of IBD. Scand J Gastroenterol. 2007;42:899-901


2006


Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I. Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug-Induced Clinical Relapse in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2006;4:196-202.

Kalaitzakis E, Johansson JE, Bjarnason I, Bjornsson E. Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol. 2006;41:326-30.

Fraser JS, King AL, Ellis HJ, Moodie SJ, Bjarnason I, Swift J, Ciclitira PJ.  An algorithm for family screening for coeliac disease. World J Gastroenterol. 2006;12:7805-7809

Adebayo D, Bjarnason I.   Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006;82:186-191.

Manoj K, Sigurbjornsson FT, Bjarnason I.  Leucocyte apheresis for ulcerative colitis: Where do we stand? Dig Liver Dis. 2006

Ladwa M, Takeuchi K, Bjarnason I. Non-steroidal anti-inflammatory drugs request parity with Helicobacter pylori. Scand J Gastroenterol. 2006;41:373-375

Maiden L, Bjarnason I. Capsule Enteroscopy and Crohn's Disease. Clin Gastroenterol Hepatol. 2006;4:660

Bjarnason I, Adler SN, Maiden L. Physical-chemical small bowel injury. in Keuchil M, Hagenmuller, Fleischer DE eds. Atlas of video capsule endoscopy. Springer Medizin Verlag, Heidelberg 2006:144-148.

Bjarnason I Takeuchi K, Hanai H, Suzuki Y, Maiden L, Saniabadi AR.
Selective leucocyte apheresis for inflammatory bowel disease: does this spare
corticosteroids? In Bianchi-Porro G, Bosani M, Pastor L eds. La gastropatia
da FANS: dopo il caso Vioxx.  La colitie ulcerosa: progressi therapeutici.
Edizoni Liberia Cortina Verona 2006:81-91

2005


Atanasova BD, Li AC, Bjarnason I, Tzatchev KN, Simpson RJ. Duodenal ascorbate and ferric reductase in human iron deficiency. Am J Clin Nutr. 2005;81:130-133.

Takeuchi K, Bjarnason I, Laftah AH, Latunde-Dada GO, Simpso RJ, Mckie AT. Expression of iron absorption genes in mouse large intestine. Scand J Gastroenterol 2005;40:169-177

Weller C, Oxlade N, Dobbs SM, Dobbs RJ, Charlett A, Bjarnason I. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunology and Medical Microbiology.
2005;44:129-135

Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I.  Quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-1178.

Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocyte apheresis as a non-pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy? J Clin Apheresis. 2005;20:171-184

Dobbs RJ, Dobbs SM, Weller C, Bjarnason I, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, Price AB. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter. 2005;10:267-275.

Bjarnason I, Charlett A, Dobbs RJ, Dobbs SM, Ibrahim MA, Kerwin RW, Mahler RF, Oxlade NL, Peterson DW, Plant JM, Price AB, Weller C. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study. Helicobacter. 2005;10:276-287

Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, Bjarnason I. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter. 2005;10:288-297.

Bjornsson E, Cederborg A, Akvist A, Simren M, Stotzer PO, Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2005;40:1090-1094

Bjarnason I, Thjodleifsson B. The murky world of COX-2 selective agents. Immunopharmacology. 2005;13:381-393 Bjarnason I, Bjarnason A. Unorthodox treatment for irritable bowel syndrome? Eur J Gastroenterol Hepatol. 2005;17:1-3.

Takeutchi K, Adler SN, Bjarnason I. Nonsteroidal antiinflammatory
drug-induced small and large bowel damage. In Bayless TM, Diehl AM.
Advanced therapy in Gastroenterology and liver disease. BC Decker Inc,
Hamilton 2005;364-366

Bjarnason I, Takeuchi K, Maiden L, Adler S. Drug-induced changes to the small and large intestine. in Clinical Gastroenterology and Hepatology. Eds: Weinstein WM, Hawkey CJ, Bosch J. Elsvier Mosby, Spain. 2005: 485-490

Bjarnason I, Biossoli F, Conforti A, Maiden L, Moore N, Moretti U, Rainsford KD, Takeutchi K, Velo GP. Adverse reactions and their mechanisms for nimesulide. In: Nimesulide – Actions and uses. Rainsford KD (ed). Birkhouser Verlag, Basel 2005:315-415

Bjarnason I, Maiden L, Takeuchi K. Testing the gut and its function – faecal samples – breath tests and more? in: Gastroenterology yesterday, today, tomorrow: A review and preview. Eds: Adler G, Blum AL, Blum HE, Leuschner U, Manns MP, Mossner J, Sartor RS, Scholmeric J. Falk symposium 144, Springer, Dordreich, The Netherlands 2005:253-266


2004


Takeuchi K, Ladwa M, Bjarnason I. Fecal Calprotectin and IBD - A viewpoint. IBD Monitor 2004;5:91-95

Premchand P, Takeuchi K, Bjarnason I. Selective blood-letting for severe ulcerative colitis. Scand J Gastroenterol. 2004;39:416-417

Walley M, Hotz-Behofsits C, Simpson R, Bjarnason I. Nitric oxide: potential role for reducing gastro-enteropathy. Inflammopharmacology. 2003;11:429-436.

Jonzon B, Bjarnason I, Hawkey C, Jones J, Goddard A, Fagerholm U, Karlsson P. The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology. 2003;11:437-444

Finkel Y, Bjarnason I, Lindblad A, Lange S.  Specially processed cereals: a clinical innovation for children suffering from inflammatory bowel disease? Scand J Gastroenterol. 2004 Jan;39:87-88

Premchand P, Takeuchi K, Bjarnason I. Macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur J Gastroenterol Hepatol. 2004;16:943-945.

Bjarnason I, Takeuchi K, Bjarnason A, Adler SN, Teahon K. The G.U.T. of gut. Scand J Gastroenterol. 2004;39:807-815

.Smale S, Forgacs I, Bjarnason I. Protein losing enteropathy. in Encyclopedia of Gastroenterology.  Elsevier 2004:251-254

Maiden L, Bjarnason I. COX 2 inhibition and bowel strictures.
Gut. 2004;53:1057-1058

Takeuchi K, Meera L, Bjarnason I. Predictive factors of the course and therapeutic response in inflammatory bowel disease. In Lukas M, Manns MP, Spicak J, Stange EF eds. Immunological diseases of liver and gut. Kluver Academic Publishers, Dordrecht. 2004:234-246

Johnson MW, Dewar DH, Ciclitira P, Forbes A, Nicholls RJ, Bjarnason I.
Use of fecal lactoferrin to diagnose irritable pouch syndrome: A word of caution. Gastroenterology. 2004;127:1647-1648

Takeuchi K, Maiden L, Bjarnason I. Genetic aspects of intestinal permeability in inflammatory bowel disease. In Inflammatory Bowel Disease: Crossroads of microbes. Epithelium and immune system. Novartis Foundation Symposium 263. John Wiley & Sond, Ltd. Chichester 2004: 151-163

Takeuchi K, Maiden L, Bjarnason I.  Genetic aspects of intestinal permeability in inflammatory bowel disease. Novartis Found Symp. 2004;263:151-158

2003


Hanai H, Watanabe F, Takeuchi K, Lida T, Tamada M, Iwaoka Y, Sanibadin A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte absorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clinical Gastroenterol Hepatol 2003;1:28-35

Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristleifur Kristjansson, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Sub-clinical intestinal inflammation: An inherited abnormality in Crohn’s disease relatives? Gastroenterology 2003;124:1728-1737

Sanibadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Addachi T, Shima C, Bjarnason I, Lofberg R. Adacolumn, an adsorption carrier based granulocyte and monocyte apheresis devise for the treatment of inflammatory and refractory diseases associated with leukocytes. Therap Apher Dial 2003;7:48-59

Mukhin NA, GuliaevSV, Krivosheev OG, Semenkova EN, Kogan EA, Okhotnikhova NL, Zavodnov VIa, Gmoshinskii IV, Mazo VK, Crane R, Bjarnason I.  Clinical and prognostic value of lesions in the gastrointestinal tract in systemic vascular purpura. Ter Arkh. 2003;75:50-54.

Smale S, Bjarnason I, Forgacs I, Prasad P, Mukhood M, Wong M, Ng A, Mulcahy HE. Upper gastrointestinal endoscopy performed by nurses: scope for the future?Gut. 2003;52:1090-1094.

Hotz-Behofsits CM, Walley MJ, Simpson R, Bjarnason I. COX-1, COX-2 and the topical effect in NSAID-induced enteropathy. Immunopharmacology 2003;

Bjarnason I, Takeuchi K, Simpson R. NSAIDs: the Emperor’s new dogma? Gut 2003;52:1376-1378

Smale S, Bjarnason I.  Determining small bowel integrity following drug treatment. Br J Clin Pharmacol. 2003;56:284-291.

Hawkey JC, Jones IJ, Atherton CT, Slelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlson P, Bjarnason I. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003;52:1537-1542

Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O, Thjodleifsson B. Sub-clinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003;125:1598-1605

Hotz-Behofsits CM, Walley MJM, Simpson R, Bjarnason I. COX-1,COX-2 and the topical effect in NSAID-induced enteropathy. Immunopharmacology 2003;11:363-370

Bjarnason I. Innovative technologies – Capsule endoscopy. IAP Bulletin 2003:4-5

2002


Somasundaram S, Simpson R, Rafi S, Shergill J, Bjarnason I, Wrigglesworth J. 2,4-Diamino-6-hydroxy pyrimidine inhibits NSAID-induced nitrosyl-complex EPR signals and ulcer in rat jejunum. BMC Gastroenterology 2002;2:8

Jacob M, Bjarnason I, Simpson RJ. Effects of indomethacin on energy metabolism in rat jejunal tissue in vivo. Clin Sci 2002;102:541-546

Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, intestinal integrity and pathogenesis of NSAID-enteropathy in mice. Gastroenterology 2002;122:1913-1923

Bridger S, Lee JCW, Bjarnason I, Lennard Jones JE, Macpherson AJ. In siblings with similar susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-smokers ulcerative colitis. Gut 2002;51:21-25

Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology. 2002;123:450-460.

Taylor RM, Bjarnason I, Cheeseman P, Davenport M, Baker AJ, Mieli-Vergani G, Dhawan A. Intestinal permeability and absorptive capacity in children with portal hypertension. Scand J Gastroenterol. 2002;37:807-811.

Thjodleifsson B, Davidsdottir K, Agnarsson U, Sigthorsson G, Kjeld M, Bjarnason I. Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine. Gut. 2002;51:816-817

Bjarnason I, Menzies IS. Causes and consequences of altered gut permeability. in Brostoff J,  Challacombe S (eds). Food allergy and intolerance (2nd edition). Saunders, Elsevier Science, London, 2002:241-257

Bjarnason I, Cederborg A, Akvist A, Smale S. Intestinal barrier function. in Biology of the intestine in growing animals. Zabielski R, Gregory PC, Westrom B (eds). Elsevier, Amsterdam 2002:657-693

2001


Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddson E, Price AB, Fitzgerald DJ, Bjarnason I. Selective inhibition in humans of COX-2 is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-348

Tibble J, Sigthorsson G, Foster R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood testing in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-408

Jacob M, Bjarnason I, Rafi S, Wrigglesworth J, Simpson RJ. A study of the effects of indomethacin on liver mitochondria from rats, mice and humans. Aliment Pharmacol Ther 2001;15:1837-1842

Jacob M, Bjarnason I, Simpson R. Effect of indomethacin on energy metabolism in the rat and human jejunal tissue in vitro. Clin Sci 2001;101:493-498

Smale S, Natt RS, Orchard T, Russell AS, Bjarnason I. Spondylarthropathy and inflammatory bowel disease. Arthr Rheumat 2001;44:2728-2736

Tibble J, Sigthorsson G, Caldwell C, Palmer RH, Bjarnason I. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats. Aliment Pharmacol Ther 2001;15:2001-2008

Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit gastrointestinal lesions and extend the therapeutic index of mycophenolate. Trasnsplant Proc. 2001;33:3238-3240

Smale S, Bjarnason I. Nonsteroidal antiinflammatory drugs, enterocolonic ulceration, and inflammatory bowel disease. In Bayless TM, Hanauer SB eds. Advanced therapy of inflammatory bowel disease. BC Decker, Hamilton. 2001:625-629

Bjarnason I, Rainsford KD. COX-2 inhibitors and the gastrointestinal tract. Gut 2001;48:451

Tibble J, Bjarnason I. Faecal calprotectin as an index of intestinal inflammation. Drugs Today; 2003;37:85-96

Bjarnason I, Sherwood R. Faecal calprotectin: a significant step in the non-invasive assessment of intestinal inflammation. J Pediatr Gastroenterol 2001;33:11-13

Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460-465

Smale S, Tibble J, Sigthorsson G, Bjarnason I. Epidemiology and different diagnosis of NSAID-induced injury to the mucosa of the small bowel. Best Pract Res Clin Gastroenterol 2001;15:721-738

Bjarnason I, Rainsford KD. Are cyclo-oxygenase-2 inhibitors free of gastrointestinal side effects? West J Med 2001;175:267-268


2000


Somasundaram S, Sigthorsson G, Simpson R, Watts J, Jacob M, Tavares IA, Rafi S, Roseth A, Foster R, Price AB, Wrigglesworth JM, Bjarnason I. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000;14:639-650

Taylor C, Hodgson K, Sharpstone D, Sigthorsson G, Coutts M, Sherwood R, IMenzies IS, Gazzard B, Bjarnason I. The prevalence and severity of intestinal disaccharidase deficiency in HIV-infected subjects. Scand J Gastroenterol 2000;35:599-606

Sigthorsson G, Tibble J, Mahmud T, Bjarnason I. NSAID-induced gastrointestinal damage: the biochemical consequences of the “ion trapping” hypothesis. Immunopharmacology 2000;8:31-41

Tibble J, Sigthorsson G, Bridger S, Fagerhol M, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22

Thomas P, Rihani H, Roseth A, Sigthorsson G, Price A, Nicholls RJ, Bjarnason I. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum. 2000;43:214-220

Tibble JA, Sigthorsson G, Foster R, Bjarnason I. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000;35:802-807

Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-513

Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Boognese J, Bjarnason I. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-532

Borrelli F, Welsh NJ, Sigthorsson G, Simpson R, Palizban A, Bjarnason I, Tavares IA. Gastric acid secretion in cyclooxygenase-1 deficient mice. Alim Pharmacol Therap 2000;14:1365-1370

Sigthorsson G, Thjodleifsson B, Mahmud T, Bjarnason I. Gastrointestinal tolerability of nimesulide, a selective cyclooxygenase-2 inhibitor, in experimental animals and man. Immunopharmacology 2000;8:175-187

Tibble J, Forgacs I, Bjarnason I, Przemioslo R. The effects of a pre-assessment clinic on non-attendance rates for day-case surgery. Endoscopy 2000;32:963-965

Smale S, Tibble J, Bjarnason I. Small intestinal permeability. Curr Opin Gastroenterol 2000;16:134-139

Tibble J, Smale S, Bjarnason I. Value of intestinal function tests in inflammatory bowel disease. Infl Bowel Dis Monitor 2000;1:99-103

1999


Sharpstone D, Neild P, Crane R, Taylor C, Abraham H, Gazzard B, Bjarnason I. Gastric emptying, and small bowel transit, absorption and permeability in AIDS patients with and without diarrhoea.  Gut 1999;45:70-76

Murphy B,Taylor C, Crane C, Kizza A, Bjarnason I. A comparison between intestinal function in HIV seropositive patients in Kampala and London. Scand J Gastroenterol 1999;34:491-495

D'Antiga L. Dhawan A, Davenport M, Mieli-Vergani G, Bjarnason I. Intestinal absorption and permeability in paediatric short bowel syndrome. J Paed Gastroenterol Nutr 1999;29:588-593

Tibble JA, Foster R, Sigthorsson G, Scott D, Roseth A, Bjarnason I. Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy. Gut 1999;45:362-366

Bjarnason I, Thjodleifsson B. Gastrointestinal toxicity of NSAIDs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology 1999;38 (Suppl I):24-32

Bjarnason I. Bjarnason I. Forthcoming NSAIDs: Are they really devoid of side effects. Ital J Gastroenterol & Hepatol. 1999;31(Suppl. 1):S27-36

Macpherson AJS, Maloy KJ, Bjarnason I. Intolerance of the dirty intestines. Gut 1999;44:774-775

Bjarnason I, Menzies IS. Causes and consequences of altered intestinal permeability. in: Brostoff J, Challacombe S (eds): Textbook of Food Allergy, second edition. WB Saunders, London. In press.

Bjarnason I, Price AB. Small intestinal inflammation, ulcers and strictures. in: Marsh MN (ed). The small intestine. Blackwell Science, Boston. I

Bjarnason I, Prescribing NSAIDs: Intestinal toxicity and emerging safer anti-inflammatory drugs. CME Rheumatology & Arthritis.

Bjarnason I, Metabolic bone disease in patients with inflammatory bowel disease. Rheumatology 1999;38:801-804

Scarpignatio C, Bjarnason I, Bretagne J.-F., De Pouvourville G, Garcia Rodrigues LA, Goldstein JL, Muller P, Simon B. Towards a GI safer anti-inflammatory therapy. Gastroenterol Int 1999;12:186-214

Tibble J, Bjarnason I, Side-effects of drugs on the small intestine. Prescriber 1999;10:79-84.

Tibble J, Smale S, Bjarnason I, Adverse effects of drugs on the small bowel. Adverse Drug Reaction Bulletin. 1999; no 198:755-758

1998


Gabe S, Bjarnason I,  Redger JM, Toloughamari Z, Johnson PJ, Barkley GR, Williams R, Silk DBA. The effects of tacrolimus on mitochondrial and intestinal barrier function. Gastroenterology 1998: 115:67-74

Sigthorsson G, Jacob M, Wrigglesworth J, Somasundaram S, Tavares I, Foster R, Roseth A, Rafi S, Mahmud T, Simpson R, Bjarnason I. Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. Scand J Gastroenterol 1998;33:728-735.

Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998;43:506-511

Mahmud T, Somasundaram S, Sigthorsson G, Simpson RJ, Foster R, Tavares IA, Roseth A, Hutt AJ, Jacob M, Pacy J, Scott DL, Bjarnason I. Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID-enteropathy in the rat by stereoselective inhibition of cyclooxygenase. Gut 1998;43:775-782

Gabe S, Jacob M, Bjarnason I. The intestinal permeability barrier-what is measured, and what does it mean? in: Gut and the liver. Blum HE, Bode Ch, Bode JCh, Sartor RB (eds.). Falk Symposium No 100. Kluwer Academic Publishers, Dordrech 1998:31-46

Jacob M, Simpson R, Bjarnason I. Nonsteroidal anti-inflammatory drugs, cyclooxygenase selectivity and gastrointestinal toxicity. Ital J Gastroenterol & Hepatol. 1998;30:12-18

Bridger S, Bjarnason I. Prescribing NSAIDs: recent insights into gastrointesatinal toxicity. National Association of Fundholding Practices Year Book. 1998;5:135-141.

1997


Bjarnason I, Macpherson A, Rothman H, Schupp J, Hayllar J. A randomised, double blind, crosseover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclo-oxygenase-2 inhibitor, flosulide, and naproxen. Scan J Gastroenterol 1997;32:126-130

Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomass N, Forgacs I, Moniz C. Reduced bone mineral density in patients with inflammatory bowel disease. Gut 1997;40:228-233

Somasundaram S, Rafi SS, Jacob M, Sigthorsson G, Mahmud T, Sherwood R, Price AB, Macpherson A, Scott D, Wrigglesworth JM, Bjarnason I. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 1997;40:608-613.

Sherwood R, Marsden JT, Stein CA, Somasundaram S, Aitken C, Oxford JS, Menzies IS, Bjarnason I. AZT absorption and small intestinal function in HIV infected subjects. J Antiviral Chemistry and Chemotherapy. 1997;8:327-332

Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M,  Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID-induced injury to the rat intestine. Gut 1997;41:344-353

Bjarnason I, Macpherson A, Price AB. Non-steroidal anti-inflammatory drug-induced enteritis. In Inflammatory bowel diseases (3 rd edition). Eds: Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW. Churchill Livingstone, New York. 1997:437-442

Bjarnason I. NSAIDs, COX and GI safety. Prescriber 1997; (suppl):4-6

Bjarnason I. The effects of nonsteroidal anti-inflammatory drugs on the small intestine: clinical implications. Arthritis care. 1997;6:1-4

1996


Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-375

Teahon K, Somasundaram S, Smith T, Menzies I, Bjarnason I. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut 1996;38:864-869

Bjarnason I, Batt R, Catt S, Macpherson A, Maxton D, Menzies IS. Evaluation of differential disaccharide excretion in urine for non-invasive assessment of intestinal disaccharidase activity caused by a-glucosidase inhibition, primary hypolactasia and coeliac disease. Gut 1996;39:374-381

Bjarnason I, Sharpstone D, Francis N, Marker A, Taylor C, Barrett M, Macpherson A, Baldwin C, Menzies IS, Crane R, Smith T, Pozniak A, Gazzard B. Intestinal inflammation, ileal structure and function in HIV/AIDS 1996;10:1385-1391

Mahmud T, Rafi S, Scott DL, Wrigglesworth JM, Bjarnason I. NSAIDs and uncoupling of oxidative phosphorylation. Arth Rheum 1996;39:1998-2003

Bjarnason I, Peters TJ. Influence of anti-rheumatic drugs on gut permeability and on gut associated lymphoid tissue. In Veys EM, Mielants H (eds). Gut inflammation in rheumatology. Bailliers Clinical Rheumatology, Bailliere Tindall, London. 1996:165-176

Mahmud T, Scott D, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-213

Bjarnason I, Menzies I, Macpherson A. Pouch permeability: breaching barriers to understanding pouchitis? Gut 1996;39:338-339

Bjarnason I, Macpherson AJS. Intestinal absorption-permeability tests and nutrition. Clinical Nutrition 1996;5:63-66

Bjarnason I, Macpherson A. Intestinal permeability: Tests for diagnostic leaks or leaky diagnostic tests? Zeits Gastroenterol 1996;35 (suppl. 4):54-59

Bjarnason I. Intestinal permeability and intestinal inflammation: Making sense out of the facts. In Bjornsson OG (ed). Davids book. Icelandic University Press, Reykjavik 1996:189-224

Bjarnason I, Hayllar J. Early pathogenic events in NSAID-induced gastrointestinal damage. Ital J Gastroenterol 1996;28 (Suppl 4):19-22

Hayllar J, Bjarnason I. Gastroduodenal tolerability of a highly specific cyclo-oxygenase-2 inhibitor.  Ital J Gastroenterol 1996;28 (Suppl 4):30-32

1995


Teahon K, Pearson M, Levi AJ, Bjarnason I. Practical aspects of elemental diets in patients with Crohn's disease. J Ent and Parent Nutr. 1995;19:365-368

Teahon K, Pearson M, Smith T, Levi AJ, Bjarnason I. Alterations in nutritional status and disease activity during treatment of Crohn's disease with elemental diet. Scand J Gastroenterol. 1995;30:54-60
 
Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology. 1995;108:1566-1581
 
Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I. The effect of long term misoprostol co-administration with non-steroidal anti-inflammatory drugs: a histological study. Gut: 1995;37:195-198

Somasundaram S, Hayllar J, Rafi S, Wrigglesworth JM, Macpherson AJS, Bjarnason I. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis. Scand J Gastroenterology. 1995;30:289-299

Khoo UY, Bjarnason I, Donaghy A, Williams R, Macpherson A. Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis. Gut 1995;37:63-70

Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I. Effect of long term misoprostol co-administration with non-steroidal anti-inflammatory drugs: a histological study. Gut 1995;37:195-198

Mayall TP, Bjarnason I, Peters TJ, Macpherson AJM. Mitochondrial gene expression in small intestinal epithelial cells. Biochem J 1995;308:665-671

Keating J, Bjarnason I, Somasundaram S, Macpherson A, Francis N, Price AB, Sharpstone D, Smithson J, Menzies IS, Gazzard BG. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea. Gut 1995;37:623-629

Bjarnason I, Macpherson A, Teahon K. The grand unification theory (GUT) of the pathogenesis of small bowel disease and the relation to Crohn's disease. Focus on Gastroenterology. Proceedings of Waltham/ESCG Symposia. 1995:18-25

Bjarnason I, Macpherson A, Menzies IS. Intestinal permeability: The basics. Can J Gastroenterol 1995;9:203-212

Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:521-522

Bjarnason I, Macpherson A. Alcohol and small intestinal permeability. In: Preedy VR, Watson RR (eds). Alcohol and the gastrointestinal tract. CRC Press, Boca Raton 1996:219-234.

Macpherson AJS, Bjarnason I. Basic science 1, clinical gastroenterology 0. Lancet 1995;346:S6


1994


Ohri SK, Somasundaram S, Koak Y, Macpherson A, Keogh BE, Taylor KM, Menzies IS, Bjarnason I. The effect of intestinal hypoperfusion during cardiopulmonary bypass surgery on saccharide permeation and intestinal permeability in man. Gastroenterology 1994;106:318-323.

Hayllar J, Smith T,  Macpherson A, Price AB, Gumpel MJ,  Bjarnason I. NSAID-induced small intestinal inflammation and blood loss; the effect of sulphasalazine and other disease modifying drugs. Arthr Rheumat 1994; 37:1146-1150

Wicks C, Somasundaram S, Bjarnason I, Menzies IS, Routley D, Potter D, Tan KC, Hayllar K, Williams R. Comparison of enteral feeding and total parentral nutrition after liver transplantation. Lancet: 1994;344:837-840

Bjarnason I, Maxton D, Reynolds A, Catt S, Peters TJ, Menzies IS. A comparison of 4 markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol 1994;26:630-639

Teahon K, Webster D, Price AB, Weston J, Bjarnason I. Studies on the enteropathy associated with primary hypogammaglobulinaemia. Gut 1994;35:1244-1249

Bjarnason I, Macpherson A. Treatment of nonsteroidal antiinflammatory drug induced damage to the small and large intestine. In: Bayless TM, ed.  Current Therapy in Gastroenterology and Liver Disease (4th ed).  Mosby, St Louis 1994: 295-298

Macpherson AJS, Khoo UY, Bjarnason I. Inflammatory bowel disease of mice - and men. Lancet 1994;343:130-131.

Bjarnason I. Intestinal Permeability. Gut 1994; 35 (Suppl 1):S18-S22.

Bjarnason I, Macpherson AJS. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmac Ther 1994;62:145-157.

Macpherson AJS, Bjarnason I Colonocytes in Barrett's metaplasia. Lancet 1994;344:903-904.

Bjarnason I, Price AB. The small and large intestinal pathologies of non-steroidal anti-inflammatory drug ingestion. Ann Pathol 1994;14:326-332.

Bjarnason I, Macpherson A, Menzies IS. Intestinal permeability: The basics. In: Sutherland LR, Collins SM, Martin F, McLeod RS, Targan SR, Wallace JL, Williams CN (eds). Inflammatory bowel disease. Basic research, clinical implications and trends in therapy. Kluwer Academic Press, Dordrech. 1994:53-70.

Bjarnason I. The effects of non-steroidal antiinflammatory drugs on the small and large intestine. Searle Literature Review Series 1994;1, no 2: 1-15.

1993


Ohri SK, Bjarnason I, Pathi V, et al. Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann Thorac Surg 1993;55:1080-1086.

Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance in patients with Crohn's disease. Gut 1993;34:783-787.

Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol and Hepatol 1993;5:79-84.

Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-1847.

Quinn CM, Bjarnason I, Price AB. Gastritis in patients on nonsteroidal anti-inflammatory drugs. Histopathology 1993;23:341-348.

Teahon K, Bjarnason I. Comparison of leucocyte excretion and blood loss in inflammatory disease of the bowel. Gut 1993;34:1535-1538.

Bardhan KD, Bjarnason I, Scott DL, Griffin WM, Fenn GC, Shields MJ, Morant SV. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by  misoprostol. Br J Rheumatol 1993;32:990-995.

Macpherson AJ, Bjarnason I. Danni intestinali da FANS. In: Guslandi M, Braga PC, ed.  Danni da farmaci all'apparato digerente.  Berlin: Springer-Verlag, 1993: 77-88.

Bjarnason I, Macpherson AJS, Somasundaram S, Teahon K. Non-steroidal anti-inflammatory drugs and Crohn's disease. In: Scholmeric J, Kruis  W, Goebbell H, Hohenberger W, Gross V, (eds). Inflammatory bowel diseases: Pathophysiology as basis of treatment. Falk Symposium No 67. Lancaster: Kluwer Academic Publishers, 1993:208-222.

Bjarnason I, Macpherson AJ. Delivery, safety and efficacy of 5-aminosalicylate preparations. Immunopharmacology 1993;2:277-287.

Bjarnason I, Macpherson AJ. Sulphasalazine and new 5-aminosalicylic acids in inflammatory bowel disease. Hospital Update Plus 1993;19:60-61.

Bjarnason I, Macpherson A, Somasundaram S, Hayllar J. Lower bowel toxicity of nonsteroidal anti-inflammatory drugs. In: Lewis, Furst D, ed.  Non-steroidal anti-inflammatory drugs: Mechanisms and clinical uses (2nd ed) New York: Marcel Dekker, 1993: 145-157.

Bjarnason I, Macpherson A, Somasundaram S, Teahon K. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease. Can J Gastroenterol 1993;7:160-169

1992


Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut. 1992;33:320-323.

Bjarnason I, Smethurst P, Macpherson A, Walker F, McElnay JC, Passmore AP, Menzies IS, Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992;102:1546-1550.

Bjarnason I, Hayllar J, Smethurst P, Price AB, Gumpel MJ. Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut 1992;33:1204-1208.

Wassif W, Bjarnason I. A comparison of the effects of aceclofenac and diclofenac on gastrointestinal blood loss. Br J Clin Research. 1992;3:109-114.

Macpherson AJS, Chester KA, Robson L, Bjarnason I, Malcolm ADB, Peters TJ. Increased expression of C-myc proto-oncogene in biopsies of ulcerative colitis and Crohn's disease. Gut 1992;33:651-656.

Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs. Rational and clinical implications. Drug Safety. 1992;7:86-105.

Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Effects of nonsteroidal anti-inflammatory drugs on permeability of the small intestine in humans. J Rheumatol 1992;19 (Suppl 36):83-84.

Macpherson AJ, Bjarnason I, Forgacs IC. Discovery of the gene for familial adenomatous polyposis. Br Med J. 1992;304:858-859.


1991


Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. The importance of local versus systemic effects of non-steroidal anti-inflammatory drugs to increase intestinal permeability in man. Gut. 1991;32:275-277.

Bjarnason I, Smethurst P, Menzies IS, Peters TJ. The effect of polyacrylic acid polymers (carbopol) on small intestinal function and permeability changes caused by indomethacin. Scand J Gastroenterol. 1991;26:685-688.

Teahon K, Pearson M, Levi AJ, Bjarnason I. Elemental diet in the management of Crohn's disease during pregnancy. Gut. 1991;32:1079-1081.

Teahon K, Smethurst P, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991;101:84-89.

Duane P, Teahon K, Crabtree JE, Levi AJ, Heatley RV, Bjarnason I. The relationship between nutritional status and serum soluble interleukin-2 receptor concentrations in patients with Crohn's disease treated with elemental diet. Clinical Nutrition. 1991;10:222-227.

Bjarnason I, Rooney PJ. NSAID enteropathy - Not just a pain in the gut. J Rheumatology. 1991;18:796-798.

Bjarnason I. Bowel bears brunt of NSAID insult. Hospital Doctor 1991;11:20-21.

Teahon K, Bjarnason I, Levi AJ. The role of enteral and parentral nutrition in Crohn's disease and ulcerative colitis. Progress in inflammatory disease. 1991;11:1-8.

Bjarnason I. The significance of NSAID damage to the small intestine. Geriatric Medicine. 1991;21:12-15.

Bjarnason I. NSAID-Induced damage in the lower bowel. Physician. 1991;21:280-281.

Hayllar J, Bjarnason I. Sulphasalazine in ulcerative colitis; In memoriam? Gut 1991;32:462-46

1990


Bjarnason I, Hopkinson N, Zanelli G, Prouse P, Gumpel MJ, Levi AJ. The treatment of non-steroidal anti-inflammatory drug-induced enteropathy. Gut. 1990;31:777-780.

Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years experience with elemental diet in the management of Crohn's disease. Gut. 1990;31:1133-1137.

Marsh MN, Bjarnason I, Ellis A, Baker R, Peters TJ. Studies of intestinal lymphoid tissue, X-HLA status, mucosal morphology, permeability and epithelial lymphoid populations in first degree coeliac sprue relatives. Gut. 1990;31:32-36.

Levi S, DeLacey G, Price AB, Gumpel MJ, Levi AJ, Bjarnason I. 'Diaphragm like' strictures of the small bowel in patients treated with non-steroidal anti-inflammatory drugs. Br J Radiol 1990;63:186-189.

Smith T, Bjarnason I. Experience with the use of a gastrointestinal marker (51CrCl3) in a combined study of ileal function using 75SeHCAT and 58CoVitB12 measured by whole body counting. Gut. 1990;31:1120-1125.

Bjarnason I. Experimental evidence of the benefit of misoprostol beyond the stomach in humans. J Rheumatol 1990;17 (Suppl 20):38-41.

Bjarnason I. NSAID induced enteropathy. in: Peters TJ, ed.  The cell biology of inflammation in the gastrointestinal tract.  Hull: Corners publications, 1990: 345-360.

Bjarnason I. Intestinal permeability barriers. in: Peters TJ, ed.  The cell biology of inflammation in the gastrointestinal tract.  Hull: Corners Publications, 1990: 127-142.

Bjarnason I, Fehilly B, Smethurst P, Levi AJ. The importance of local versus systemic effects of NSAIDs to increase small intestinal permeability. Br J Rheumatol 1990;27 (Suppl 2):112-113.

Bjarnason I. NSAIDs: More than just a pain in the stomach. Arthritis in focus. 1990;1:2-3.

Bjarnason I. NSAID risk lies beyond duodenum. Doctor 1990;8th Nov:29.

1989


Bjarnason I, Smethurst P, Fenn GC, Lee CF, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1989;34:407-411.

Scadding G, Bjarnason I, Brostoff J, Levi AJ, Peters TJ. Intestinal permeability to 51CrEDTA in food intolerant patients. Digestion. 1989;42:104-109.

Bjarnason I, Peters TJ. Intestinal permeability, NSAID enteropathy and inflammatory bowel disease. Gut 1989;30:22-28.

Lambert MT, Bjarnason I, Connelly J, et al. Small intestinal permeability in schizophrenia. Br J Psychiatry 1989;155:619-622.

Teahon K, Bjarnason I. Peptic ulcer disease. Care of the elderly. 1989;1:132-134.

Bjarnason I, Smethurst P, Clarke P, Menzies IS, Levi AJ, Peters TJ. Effect of prostaglandins on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol 1989;29 (Suppl 164):97-103.

Bjarnason I, Macpherson AJ. The changing side effect profile of NSAIDs. A new approach for the prevention of a new problem. Scand J Gastroenterol 1989;24 (Suppl 163):56-64.

1988


Bjarnason I, Zanelli G, Smethurst P, et al. Clinico-pathological features of NSAID induced small intestinal strictures. Gastroenterology 1988;94:1070-1074.

Bjarnason I, Zanelli G, Smethurst P, et al. Clinico-pathological features of non-steroidal anti-inflammatory drug-induced small intestinal strictures. Gastroenterology. 1988;94:1070-1074.

Lang J, Price AB, Levi  AJ, Burke M, Gumpel MJ, Bjarnason I. Diaphragm disease: the pathology of non-steroidal anti-inflammatory drug-induced disease of the small intestine. J Clin Pathol. 1988;41:516-526.

Bjarnason I, Levi S, Smethurst P, Menzies IS, Levi AJ. Vindaloo and you. Br Med J. 1988;297:1629-1631.

Bjarnason I, Teahon K. New non-steroidal drug therapies in inflammatory bowel disease: facts, fiction and potential. Internal medicine for the specialist. 1988;9:104-117.

Levi S, Bjarnason I, Swinson CM, Polak JM, Murray W, Levi AJ. Malignant pancreatic somatostatinoma in a patient with dermatitis herpetiformis and coeliac disease. Digestion 1988;39:1-6.

Bjarnason I. Non-steroidal anti-inflammatory drug induced small intestinal inflammation in man. In: Pounder R, ed.  Recent advances in gastroenterology - 7.  London: Churchill Livingstone, 1988: 23-46.

Bjarnason I, Price AB. The effect of NSAIDs on the large intestine. Gastrointestinal futures and clinical practice. 1988;3:7-10.

Peters TJ, Bjarnason I. Uses and abuses of intestinal permeability tests. Can J Gastroenterol 1988;2:127-132.


1987


Bjarnason I, Zanelli G, Smith T, et al. Non-steroidal anti-inflammatory drug induced intestinal inflammation in humans. Gastroenterology. 1987;93:480-489.

Raja K, Bjarnason I, Simpson RJ, Peters TJ. In vitro measurement and adaptive response of iron uptake by mouse intestine. Cell Biochem Funct. 1987;5:69-76.

Smith T, Bjarnason I, Hesp R. Critical analyses of a combined test (75SeHCAT and 58CoB12) of ileal function using a whole body counter. Clin Phys Physiol Meas. 1987;8:159-171.

Bjarnason I, Zanelli G, Prouse P, et al. Blood and protein loss via small intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987;ii:711-714.

Bjarnason I, Zanelli G, Smith T, et al. The pathogenesis and consequences of NSAID induced small intestinal inflammation. Scand J Rheumatol. 1987;(Suppl 69):55-62.

Bjarnason I, Peters TJ. Helping the mucosa make sense of macromolecules. Gut 1987;28:1057-1061.


1986


Bjarnason I, Marsh MN, Price A, Levi AJ, Peters TJ. Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis. Gut. 1986;26:1214-1219.

Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. The effect of NSAIDs and prostaglandins on the permeability of the human small intestine. Gut. 1986;27:1292-1297.

Zanelli G, Bjarnason I, Smith T, Crawley JC, Levi AJ, Copeland RI. Technetium-99m labelled porphyrin as an imaging agent for occult infections and inflammation. Nuclear Med Commun. 1986;7:17-24.

Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS. Lactulose, 51CrEDTA, L-rhamnose and polyethylene glycol 400 as probe markers for "in vivo" assessment of human intestinal permeability. Clin Sci. 1986;71:71-80.

Macpherson AJM, Bjarnason I, Peters TJ. The subcellular distribution and levels of calmodulin in jejunal biopsies from control subjects and patients with coeliac disease. Clin Chim Acta 1986;159:133-138

Zanelli G, Bjarnason I, Ellison D, Levi AJ. New radiosotope tests: new gastrointestinal diseases. in: Malagutty P, Scigaretta G, Abbati A, Furno A, ed.  New radioisotope tests in gastroenterology.  Italia: Masson, 1986: 75-81.

Bjarnason I, Peters TJ, Levi AJ. Intestinal permeability; clinical correlates. Dig Dis 1986;4:83-92.

Bjarnason I, Smethurst P, Levi AJ. Measurment of intestinal permeability with special reference to 51CrEDTA. In: Malgutty P, Scigaretta G, Abbati A, Furno A, ed.  New radioisotope tests in gastroenterology.  Italia: Masson, 1986: 480-489.

Bjarnason I, Zanelli G, Prouse P, Williams P, Gumpel MJ, Levi AJ. The effect of NSAIDs on the human small intestine. Drugs. 1986;32 (Suppl 1):35-41.

Zanelli G, Bjarnason I, Smith T, Crawley J, Levi AJ. 99mTc-labelled synthetic porphyrins for the localization of occult infection and inflammation. In: Nicolini M, Bandoli G, Mazzi U, ed.  Technetium in chemistry and nuclear medicine.  Raven Press, 1986: (vol 2):249-252


1985


Bjarnason I, Smethurst P, Levi AJ, Peters TJ. Intestinal permeability to 51CrEDTA in rats with experimentally-induced enteropathy. Gut. 1985;26:579-585.

Patel EK, Bruce SE, Bjarnason I, Peters TJ. Rat gastrointestinal transglutaminase: demonstration of enzyme activity and cell and tissue distribution. Cell Biochem Funct. 1985;3:199-203.

Bjarnason I, Goolamali SK, Levi AJ, Peters TJ. Intestinal permeability in patients with atopic eczema. Br J Dermatol. 1985;112:291-297.

Bruce SE, Bjarnason I, Peters TJ. Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specifity with special relation to gliadin and coeliac disease. Clin Sci 1985;68:573-579.

Peters TJ, Bjarnason I. Intestinal permeability. In: Hunter JO, Allin-Jones V, ed.  Food and the gut.  Oxford: Balliere Tindall, 1985: 30-44

1984


Bjarnason I, Peters TJ. In vitro determination of intestinal permeability: Demonstration of a persisting defect in patients with coeliac disease. Gut. 1984;25:145-150.

Bjarnason I, Cotes M, Knowles S, Reed S, Peters TJ. Giant lymph node hyperplasia (Castleman's disease) of the mesestery. Observations on the associated anaemia. Gastroenterology. 1984;87:216-223.

Bjarnason I, Ward K, Peters TJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet. 1984;i:179-182.

Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis; effects of non-steroidal anti-inflammatory drugs. Lancet 1984;ii:1171-1174.

Peters TJ, Bjarnason I. Biochemical approach to the investigation of intestinal disease. In: Batt RM, Lawrence TJL, ed.  Function and dysfunction of the small intestine.  Liverpool: Liverpool University Press, 1984: 199-218.

Peters TJ, Bjarnason I. Coeliac syndrome: biochemical mechanisms and the missing peptidase hypothesis revisited. Gut. 1984;25:913-918.

1983


Bjarnason I, Jonsson S, Hardarsson T. Cardiac arrhythmias in hypertrophic cardiomyopathy. Br Heart J. 1982;48:198-203.

Bjarnason I, Peters TJ, Veall N. A persistent defect of intestinal permeability in coeliac disease as demonstrated by a 51Cr-labelled EDTA absorption test. Lancet. 1983;i:323-325.

Bjarnason I, O'Morain C, Levi AJ, Peters TJ. The absorption of 51Cr EDTA in inflammatory bowel disease. Gastroenterology 1983;85:318-322.

Peters TJ, Bjarnason I. Membrane disorders: a new approach to their study in man. in: Masson M, ed. Biologie Prospective. Paris: Pont-A-Mousson, 1983: 909-920.

1982


Bjarnason I, Magnusson B, Bjornsson S. Idiopathic chronic active hepatitis in Iceland. Acta Med Scand. 1982;211:305-307.

Bjarnason I, Jonsson S, Hardarsson T. The mode of inheritance of hypertrophic cardiomyopathy in Iceland: An echocardiographic study. Br Heart J. 1982;47:122-129.

1981


Bjarnason I, Magnusson B, Bjornsson S. The significance of histologic chronic active hepatitis in Iceland. Icelandic Med J 1981;67:193-194.

Bjarnason I, Bjornsson S. Oesophageal ulcers. Acta Med Scand 1981;209:431-432.

Bjarnason I, Jonsson S, Hardarson T. Hypertrophic cardiomyopathy. A clinical and echocardiographic study. Icelandic Med J. 1981;67:99-105.

Bjarnason I, Jonsson S, Hardarson T. 24 hour electrographic monitoring in patients with hypertrophic cardiomyopathy. Icelandic Med J. 1981;67:216-221

1980


Bjarnason I, Hallgrimsson J. Hypertrophic cardiomyopathy. An autopsy study of the years 1966-1978. Icelandic Med J. 1980;66:205-208